

Study Population

- Adult patients with uncontrolled hypertension and established CV disease or at high risk
- Office systolic BP ≥ 140 mmHg on stable treatment (≥ 2 antihypertensive medications, one of which is a diuretic)
- Excluded: eGFR < 30 mL/min/1.73m², potassium > 4.8 mEq/L



Randomize 1:1 (n $\approx$ 11,000)

Zilebesiran SC 300 mg Q6M
+ standard of care

Placebo SC Q6M
+ standard of care

Minimum follow-up: 2 years



Primary Outcome: CV death, nonfatal MI, nonfatal stroke, or HF event